Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Foghorn Therapeutics (FHTX) Total Current Liabilities (2020 - 2025)

Foghorn Therapeutics (FHTX) has 6 years of Total Current Liabilities data on record, last reported at $59.7 million in Q4 2025.

  • For Q4 2025, Total Current Liabilities fell 10.82% year-over-year to $59.7 million; the TTM value through Dec 2025 reached $59.7 million, down 10.82%, while the annual FY2025 figure was $59.7 million, 10.82% down from the prior year.
  • Total Current Liabilities reached $59.7 million in Q4 2025 per FHTX's latest filing, down from $85.1 million in the prior quarter.
  • Across five years, Total Current Liabilities topped out at $85.1 million in Q3 2025 and bottomed at $16.3 million in Q1 2021.
  • Average Total Current Liabilities over 5 years is $52.5 million, with a median of $55.2 million recorded in 2022.
  • Peak YoY movement for Total Current Liabilities: surged 195.39% in 2022, then decreased 10.82% in 2025.
  • A 5-year view of Total Current Liabilities shows it stood at $48.7 million in 2021, then increased by 13.38% to $55.2 million in 2022, then grew by 5.85% to $58.4 million in 2023, then rose by 14.64% to $67.0 million in 2024, then dropped by 10.82% to $59.7 million in 2025.
  • Per Business Quant database, its latest 3 readings for Total Current Liabilities were $59.7 million in Q4 2025, $85.1 million in Q3 2025, and $77.8 million in Q2 2025.